2018
Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis
Shu X, Wu L, Khankari N, Shu X, Wang T, Michailidou K, Bolla M, Wang Q, Dennis J, Milne R, Schmidt M, Pharoah P, Andrulis I, Hunter D, Simard J, Easton D, Zheng W, Alicia B, Anton-Culver H, Antonenkova N, Arndt V, Aronson K, Auer P, Barrdahl M, Baynes C, Freeman L, Beckmann M, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Bogdanova N, Bojesen S, Brauch H, Brenner H, Brinton L, Broberg P, Brucker S, Brüning T, Burwinkel B, Cai Q, Caldés T, Canzian F, Carter B, Castelao J, Chang-Claude J, Chenevix-Trench G, Cheng T, Clarke C, Conroy D, Couch F, Cox D, Cox A, Cross S, Cunningham J, Czene K, Daly M, Doheny K, Dörk T, dos-Santos-Silva I, Dumont M, Dunning A, Dwek M, Earp H, Eccles D, Eliassen A, Engel C, Eriksson M, Evans D, Fachal L, Fasching P, Figueroa J, Fletcher O, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, Gapstur S, García-Closas M, Gaudet M, Ghoussaini M, Giles G, Goldberg M, Goldgar D, González-Neira A, Guénel P, Hahnen E, Haiman C, Håkansson N, Hall P, Hallberg E, Hamann U, Harrington P, He W, Hein A, Hicks B, Hillemanns P, Hogervorst F, Hollestelle A, Hoover R, Hopper J, Howell A, Huang G, Jakubowska A, Janni W, John E, Johnson N, Jones K, Jung A, Kaaks R, Kabisch M, Kerin M, Khusnutdinova E, Kitahara C, Kosma V, Koutros S, Kraft P, Kristensen V, Lambrechts D, Le Marchand L, Lindström S, Linet M, Lissowska J, Loibl S, Lubinski J, Luccarini C, Lux M, Maishman T, Kostovska I, Mannermaa A, Manoukian S, Manson J, Margolin S, Mavroudis D, Meijers-Heijboer H, Meindl A, Menon U, Meyer J, Mulligan A, Neuhausen S, Nevanlinna H, Neven P, Newman W, Nielsen S, Nordestgaard B, Olopade O, Olshan A, Olson J, Olsson H, Olswold C, Orr N, Perou C, Peto J, Plaseska-Karanfilska D, Prentice R, Presneau N, Pylkäs K, Rack B, Radice P, Rahman N, Rennert G, Rennert H, Romero A, Romm J, Saloustros E, Sandler D, Sawyer E, Schmutzler R, Schneeweiss A, Scott R, Scott C, Seal S, Seynaeve C, Smeets A, Southey M, Spinelli J, Stone J, Surowy H, Swerdlow A, Tamimi R, Tapper W, Taylor J, Terry M, Tessier D, Thöne K, Tollenaar R, Torres D, Troester M, Truong T, Untch M, Vachon C, Van Den Berg D, van den Ouweland A, van Veen E, Vincent D, Waisfisz Q, Weinberg C, Wendt C, Whittemore A, Wildiers H, Winqvist R, Wolk A, Xia L, Yang X, Ziogas A, Ziv E. Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal Of Epidemiology 2018, 48: 795-806. PMID: 30277539, PMCID: PMC6734940, DOI: 10.1093/ije/dyy201.Peer-Reviewed Original ResearchConceptsBreast cancer riskAssociated with breast cancer riskBody mass indexMendelian randomization analysisCancer riskRandomization analysisAssociation of breast cancer riskInverse associationFamily history of breast cancerGenome-wide association study consortiaAssociated with risk of type 2 diabetesBreast Cancer Association ConsortiumHistory of breast cancerFasting insulinAetiology of breast cancerType 2 diabetes riskControls of European descentRisk of type 2 diabetesWaist-hip ratioAssociation of obesityCirculating fasting insulinAssociated with riskBreast cancerIndividual-level dataGenetic instruments
2011
Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers
Spurdle A, Marquart L, McGuffog L, Healey S, Sinilnikova O, Wan F, Chen X, Beesley J, Singer C, Dressler A, Gschwantler-Kaulich D, Blum J, Tung N, Weitzel J, Lynch H, Garber J, Easton D, Peock S, Cook M, Oliver C, Frost D, Conroy D, Evans D, Lalloo F, Eeles R, Izatt L, Davidson R, Chu C, Eccles D, Selkirk C, Daly M, Isaacs C, Stoppa-Lyonnet D, Sinilnikova O, Buecher B, Belotti M, Mazoyer S, Barjhoux L, Verny-Pierre C, Lasset C, Dreyfus H, Pujol P, Collonge-Rame M, Rookus M, Verhoef S, Kriege M, Hoogerbrugge N, Ausems M, van Os T, Wijnen J, Devilee P, Meijers-Heijboer H, Blok M, Heikkinen T, Nevanlinna H, Jakubowska A, Lubiński J, Huzarski T, Byrski T, Durocher F, Couch F, Lindor N, Wang X, Thomassen M, Domchek S, Nathanson K, Caligo M, Jernström H, Liljegren A, Ehrencrona H, Karlsson P, Ganz P, Olopade O, Tomlinson G, Neuhausen S, Antoniou A, Chenevix-Trench G, Rebbeck T. Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers & Prevention 2011, 20: 1032-1038. PMID: 21393566, PMCID: PMC3089675, DOI: 10.1158/1055-9965.epi-10-0909.Peer-Reviewed Original ResearchConceptsBreast cancer riskAssociated with breast cancer riskBRCA2 mutation carriersBRCA1/2 mutation carriersCancer riskMutation carriersAssociated with risk of breast cancerElevated breast cancer riskBreast cancer risk assessmentRisk of breast cancerBARD1 Cys557Ser variantCancer prevention strategiesPooled effect estimatesCancer risk assessmentAssociated with riskModifiers of riskBRCA2 carriersBRCA1 carriersInherited BRCA1Risk modificationAnalysis of haplotypesPrevention strategiesEffect estimatesKnowledge of factorsBRCA1/2
2007
AURKA F31I Polymorphism and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study
Couch F, Sinilnikova O, Vierkant R, Pankratz V, Fredericksen Z, Stoppa-Lyonnet D, Coupier I, Hughes D, Hardouin A, Berthet P, Peock S, Cook M, Baynes C, Hodgson S, Morrison P, Porteous M, Jakubowska A, Lubinski J, Gronwald J, Spurdle A, kConFab, Schmutzler R, Versmold B, Engel C, Meindl A, Sutter C, Horst J, Schaefer D, Offit K, Kirchhoff T, Andrulis I, Ilyushik E, Glendon G, Devilee P, Vreeswijk M, Vasen H, Borg A, Backenhorn K, Struewing J, Greene M, Neuhausen S, Rebbeck T, Nathanson K, Domchek S, Wagner T, Garber J, Szabo C, Zikan M, Foretova L, Olson J, Sellers T, Lindor N, Nevanlinna H, Tommiska J, Aittomaki K, Hamann U, Rashid M, Torres D, Simard J, Durocher F, Guenard F, Lynch H, Isaacs C, Weitzel J, Olopade O, Narod S, Daly M, Godwin A, Tomlinson G, Easton D, Chenevix-Trench G, Antoniou A, behalf of the Consortium of Investigators of Modifiers of BRCA1/2 O. AURKA F31I Polymorphism and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study. Cancer Epidemiology Biomarkers & Prevention 2007, 16: 1416-1421. PMID: 17627006, PMCID: PMC2775799, DOI: 10.1158/1055-9965.epi-07-0129.Peer-Reviewed Original ResearchConceptsBRCA2 mutation carriersBreast cancer riskAssociated with breast cancer riskConsortium of Investigators of Modifiers of BRCA1/2BRCA2 carriersF31I polymorphismMutation carriersCancer riskModify risk of breast cancerRisk of breast cancerBreast cancer risk estimationModifiers of cancer riskAmplification of AURKABilateral prophylactic oophorectomyInactivation of BRCA1Sporadic breast tumorsPredisposition to cancerBRCA2 mutationsProphylactic oophorectomyCancer risk estimatesMenopausal statusBreast tumorsBreast cancerBRCA2Abnormal chromosome segregation
2006
BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50
Haile R, Thomas D, McGuire V, Felberg A, John E, Milne R, Hopper J, Jenkins M, Levine A, Daly M, Buys S, Senie R, Andrulis I, Knight J, Godwin A, Southey M, McCredie M, Giles G, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike M, Whittemore A, Investigators K. BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50. Cancer Epidemiology Biomarkers & Prevention 2006, 15: 1863-1870. PMID: 17021353, DOI: 10.1158/1055-9965.epi-06-0258.Peer-Reviewed Original ResearchMeSH KeywordsAdultAustraliaBreast NeoplasmsCanadaCarcinoma in SituCarcinoma, Ductal, BreastCase-Control StudiesContraceptives, OralFemaleGenes, BRCA1Genes, BRCA2Genetic Predisposition to DiseaseHeterozygoteHumansLogistic ModelsMiddle AgedMutationReceptors, EstrogenReceptors, ProgesteroneRisk FactorsSurveys and QuestionnairesTime FactorsUnited StatesConceptsRisk of breast cancerBRCA2 mutation carriersOral contraceptive useMutation carriersAssociated with breast cancer riskIncreased risk of breast cancerBreast cancerOral contraceptivesContraceptive useBreast cancer riskUnconditional logistic regressionDuration of oral contraceptive useBRCA1 mutation carriersDuration of useCase-control analysisEffects of oral contraceptivesCancer riskFamily historyModify practicesElevated riskLogistic regressionIncreased riskBRCA2Family relationshipsBRCA1